Heron Therapeutics Downgraded by Zacks to Neutral (HRTX)
Heron Therapeutics (NASDAQ:HRTX) was downgraded by Zacks to a “neutral” rating in a research report issued to clients and investors on Monday, AnalystRatings.NET reports. They currently have a $14.30 price objective on the stock. Zacks‘ price target would indicate a potential upside of 2.88% from the stock’s previous close.
Heron Therapeutics (NASDAQ:HRTX) traded up 0.37% during mid-day trading on Monday, hitting $13.63. The stock had a trading volume of 66,962 shares. Heron Therapeutics has a 1-year low of $5.60 and a 1-year high of $14.60. The stock has a 50-day moving average of $11.38 and a 200-day moving average of $9.09.
Separately, analysts at Leerink Swann initiated coverage on shares of Heron Therapeutics in a research note on Monday, February 3rd. They set an “outperform” rating on the stock.
Heron Therapeutics Inc, formerly A.P. Pharma, Inc is a specialty pharmaceutical company developing pharmaceutical products using its Biochronomer polymer-based drug delivery platform.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.